Health Support Planning
The Health Support Plan is the documented outcome of the collaborative planning process to determine the level of support required for a student with specific health conditions. The plan identifies the necessary adjustments including resources and staff training around procedures for students with personal care needs and medical conditions such as asthma, diabetes, epilepsy and anaphylaxis (refer to information below about anaphylaxis).
The Allergy Aware Resource Hub
The Allergy Aware resource hub hosts the Best practice guidelines for anaphylaxis prevention and management in schools (the Guidelines). The Guidelines have been developed to provide guidance and support to schools and may be referred to when schools are reviewing and/or updating guidelines, policies or procedures.
Links to anaphylaxis training and resources are also available on the resource hub:
Other resources available via the hub include links to the ASCIA Action Plans, First Aid Plans, Treatment Plans and Checklists.
Anaphylaxis
Planning documents for use with EpiPen® adrenaline (epinephrine) auto-injectors
- ASCIA Action Plan: Anaphylaxis – EpiPen® Red
This Action Plan is EpiPen® specific. Information about how to give EpiPen® adrenaline (epinephrine) auto-injectors is provided.
This plan includes student information that can only be completed and signed by the patient's medical or nurse practitioner.
Planning documents for use with any brand of adrenaline (epinephrine) auto-injector
- ASCIA Action Plan: Anaphylaxis – Generic Red
This Action Plan is for use with any brand of adrenaline (epinephrine) auto-injector. There is a space to insert specific instructions for the prescribed device in the bottom left corner. This plan can be used if a student is prescribed an adrenaline (epinephrine) auto-injector device other than EpiPen®.
This plan includes student information that can only be completed and signed by the patient's medical or nurse practitioner.
Planning document for allergic reactions
ASCIA Action Plans should be reviewed and reissued when patients are reassessed by their doctor, and each time they obtain a new adrenaline auto-injector prescription, which is approximately every 12 to 18 months.
